Region — US. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Explore  /  Kojic Acid
Research reference — not for sale

Kojic Acid

C
lead outcome
Hyperpigmentation / melasma (appearance,…
grades vary by outcome ↓
Small molecule (non-peptide)
also called — KA · 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one · INCI: Kojic Acid
skin appearance (cosmetic)hyperpigmentation appearanceeven tone / brightening
In brief

Kojic acid (KA) is a fungal fermentation product and a long-established tyrosinase inhibitor — it works by chelating the copper the enzyme needs. Its mechanism is strong (among the most consistent tyrosinase inhibitors in comparative lab work) and there is some standalone clinical signal: a 2013 RCT found 1% kojic acid alone reduced melasma severity. But the register grade is held at C because the caveats stack higher than for any other brightener here: most efficacy data comes from 2–4%, above the EU's 1% cap (Regulation 2024/996), so compliant products are milder than the studies; it is the brightener most associated with allergic contact dermatitis; it is chemically unstable and photosensitising; and it is almost always used in combination, so isolated evidence at a compliant strength is limited. A real ingredient with a real mechanism — honestly the most caveated of the pigment set.

Legal standing, by region
European Union
Restricted — maximum 1% in leave-on face and hand products

EU Regulation 2024/996 (the same package that capped retinol at 0.3%) limits kojic acid to a maximum of 1% in leave-on face and hand products, after an SCCS review that concluded 1% is safe for consumers. Older non-compliant products were phased out. Much of kojic acid's strongest efficacy evidence comes from 2–4%, so an EU-compliant product is deliberately milder than what the studies tested.

International
Lawful cosmetic ingredient

Kojic acid is a long-established, globally recognised cosmetic brightening ingredient. Concentration limits and rules vary by region; the EU cap of 1% is the notable restriction.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Hyperpigmentation / melasma (appearance, usually in combination)
Most efficacy data comes from 2–4%, above the EU 1% cap; often used in combination
Deo 2013 randomized study — 1% kojic acid alone reduced melasma severity, with the combination against hydroquinone stronger · Gradual fading of melasma-related pigmentation
C
PIH (appearance, in combination serums)
A combination result, not kojic acid alone
Combination-serum evidence (kojic acid paired with tranexamic acid and niacinamide) · Softening of post-inflammatory marks within a combination
C
Tyrosinase inhibition (mechanism / in-vitro potency)
This grades the MECHANISM, not clinical proof; lab potency does not equal a cosmetic outcome
Saeedi 2022 review — among the most consistent tyrosinase inhibitors in comparative in-vitro work, acting by chelating the enzyme's copper cofactor · Strong, consistent enzyme inhibition in the lab
B
Standalone / EU-compliant-strength efficacy
Isolated standalone evidence at a 1% compliant strength is limited
EU Regulation 2024/996 caps kojic acid at 1%; most efficacy studies used 2–4% · Compliant products are milder than the studied strengths
C
Tolerability & stability
A caution, not a benefit. Patch test; well-packaged (opaque, air-tight) products matter because it oxidises
Nakagawa 1995 — kojic acid is the brightener most associated with allergic contact dermatitis; it is also chemically unstable and photosensitising · Higher irritation and sensitisation risk than gentler brighteners
Cosmetic claims boundary
✓ Allowed (appearance / feel)
  • for the appearance of a brighter, more even complexion
  • helps reduce the look of dark spots
  • brightening support within a combination routine
✕ Not allowed (medicinal)
  • treats melasma
  • treats hyperpigmentation
  • cures dark spots
  • bleaches skin
  • inhibits tyrosinase
  • skin-whitening

The medicinal-sounding science stays in the reference section; product copy speaks only to appearance/feel (Reg 655/2013). Different fields, never merged.

The honest part

Kojic acid is a cosmetic ingredient, framed around the appearance of tone. In the EU, Regulation 2024/996 caps it at a maximum of 1% in leave-on face and hand products; most efficacy studies used 2–4%, so EU-compliant products are milder than what was tested. It is the brightener most associated with allergic contact dermatitis, and it is unstable and photosensitising — so patch testing, well-sealed opaque packaging, and daily sunscreen matter more here than with gentler brighteners. Persistent or hormonal pigmentation such as melasma is a dermatologist's territory, and pregnancy use is best discussed with a doctor.

Identity

a compound produced by fungi during fermentation — its skin-brightening power was first noticed on the pale hands of sake brewers. It is a long-established, globally recognised depigmenting agent, and also chemically unstable (prone to oxidising and losing potency) and, in the EU, now regulated: Regulation 2024/996 — the same package that capped retinol at 0.3% — limits kojic acid to a maximum of 1% in leave-on face and hand products. For the full readable explanation of what it is and how it works, see the companion guide, what is kojic acid?

Development & history

  • Isolated in Japan in 1907 from Aspergillus oryzae (koji mould), the microorganism behind sake, miso, and soy sauce.
  • Studied seriously for skin brightening from the 1980s–1990s and adopted globally as a depigmenting cosmetic active.
  • Flagged by the EU in 2019 as a potential endocrine disruptor (over animal-study thyroid concerns); after SCCS review, concluded safe at 1% and capped there by Regulation 2024/996, with non-compliant products phased out through 2025.

Mechanism (as proposed)

it inhibits tyrosinase by chelating the copper ion the enzyme needs to function — disarming the pigment machinery by removing a critical part rather than jamming the assembly line. In comparative laboratory work it is one of the most consistent tyrosinase inhibitors, reducing melanin without cytotoxicity in cell studies. The mechanistic case is genuinely strong; the gap, as always, is between a clean lab result and a real-world cosmetic outcome — widened here by the EU 1% cap (most studies used 2–4%), its instability, and its tendency to be used in combination rather than alone.

Related reading

Sources — 4 cited
01Deo KS, Dash KN, Sharma YK, Virmani NC, Oberai C. Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety. Indian J Dermatol. 2013;58(4):281-285.
02Desai S, Ayres E, Bak H, et al. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation. J Drugs Dermatol. 2019;18(5):454-459.
03Saeedi M, Eslamifar M, Khezri K, et al. Review on the Use of Kojic Acid — A Skin-Lightening Ingredient. Cosmetics. 2022;9(3):64.
04Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995;32(1):9-13.
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated 2026-07-12.

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
Alpha ArbutinB
Small molecule (non-peptide)
Niacinamide (Vitamin B3)A
Small molecule (non-peptide)
Vitamin C (L-Ascorbic Acid)A
Small molecule (non-peptide)
Azelaic AcidB
Small molecule (non-peptide)
Retinol (Vitamin A)A
Small molecule (non-peptide)
Tranexamic AcidB
Small molecule (non-peptide)
Explore by goal
Skin & aesthetic
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we grade
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

Kojic Acid — evidence, uses & status · Vallydia